rcc
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Arnaud Méjean Head of Urology, Hôpital Européen Georges-Pompidou; Professor, Université Paris Cité · Institut du Cancer Paris CARPEM, AP-HP Centre Surgeon who led CARMENA, the trial that showed most metastatic kidney cancer patients do not benefit from removing the kidney. | Renal cell carcinoma | none | surgery | ||
Brian I. Rini Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research · Vanderbilt-Ingram Cancer Center Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer. | Renal cell carcinoma | none | immunotherapy, trialist | ||
Laurence Albiges Head of the Department of Medical Oncology, Gustave Roussy · Gustave Roussy French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials. | Renal cell carcinoma | none | hif2a, guidelines | ||
Robert J. Motzer Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center The kidney cancer trialist behind sunitinib, CheckMate 214 and CLEAR, three shifts in first-line standard of care. | Renal cell carcinoma | none | trialist | ||
Sumanta K. Pal Professor and Co-Director, Kidney Cancer Program, City of Hope · City of Hope Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy. | Renal cell carcinoma | none | swog, microbiome |